Accession Number:

AD1013966

Title:

Evaluation of the Protective Efficacy of Recombinant Vesicular Stomatitis Virus Vectors Against Marburg Hemorrhagic Fever in Nonhuman Primate Models

Descriptive Note:

Technical Report

Corporate Author:

Uniformed Services University Of The Health Sciences Bethesda United States

Personal Author(s):

Report Date:

2007-01-19

Pagination or Media Count:

184.0

Abstract:

Marburg MARV and Ebola EBOV viruses cause severe and often fatal hemorrhagic diseases for which there are currently no vaccines or therapies approved forhuman use. The reported potential of filoviruses as biological weapons Alibek, Handelmann 1999 Miller J 2001 Borio, Inglesby et al. 2002 and the recent attention drawn to outbreaks of emerging and re-emerging viruses, such as the 2004-2005 epidemic of MARV hemorrhagic fever HF in Angola WHO 2005 Towner, Khristovaet al. 2006 CDC 2005, has significantly increased public recognition of these deadly pathogens.The development of effective treatments and therapies has been an ongoing challenge since these viruses were first discovered. The requirement for biosafety level BSL-4 containment has served as a major impediment towards the development of therapeutics. To date, the only available form of treatment for filoviral HF is intensive supportive care. With continual developments of biocontainment laboratories nationwide, additional and more promising means of treatment and prevention are needed for laboratory workers. Furthermore, the recent MARV outbreak in Angola, with case fatality rates approaching 90 percent, desperately calls attention to the fact that there is acritical and pressing need for effective countermeasures against the filoviruses. This thesis entails evaluating in nonhuman NHP models a live, attenuated, recombinant vesicular stomatitis virus rVSV vector platform expressing the transmembrane glycoprotein GP gene of MARV as both a preventative vaccine and Marburg MARV and Ebola EBOV viruses cause severe and often fatal hemorrhagic diseases for which there are currently no vaccines or therapies approved for human use. The reported potential of filoviruses as biological weapons Alibek,Handelmann 1999 Miller J 2001 Borio, Inglesby et al. 2002 and the recent attention drawn to outbreaks of emerging and re-emerging viruses, such as the 2004-2005 epidemic of MARV hemorrhagic.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE